All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mm content recommended for you
Evaluating the addition of elotuzumab to KRd by MRD assessment: the future of MRD-guided treatment?
Featured:
Ben DermanVideo series
During the EHA2021 Virtual Congress, the Multiple Myeloma Hub spoke with Benjamin Derman, The University of Chicago, Chicago, US. We asked, What is the future of MRD-guided treatment?
Adding a monoclonal antibody to triple induction therapy in patients with multiple myeloma intending to undergo transplantation can achieve high overall response rates. In this video, Derman discusses a study investigating the impact of the addition of elotuzumab to KRd (carfilzomib + lenalidomide + dexamethasone) in managing complete response rates and/or MRD negativity rates regardless of transplant eligibility and high-risk cytogenetics.
More from this series:
